NCT00789256View on ClinicalTrials.gov

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Melphalan

Melphalan: 2mg orally, once daily

DRUG

Bortezomib

Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11

DRUG

Melphalan and bortezomib

Trial Locations (2)

32256

Integrated Community Oncology Network, Jacksonville

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00789256 - Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | Biotech Hunter | Biotech Hunter